Leafix Medical

Company Overview

Snapshot

Founded in January 2025 by Ron Szekely, Leafix Medical operates with 1–10 employees. The company has raised $6.5M across two funding rounds from one investor. In July 2025, Leafix Medical secured a Seed funding round.

Business overview

Leafix Medical is a Health Tech & Life Sciences company focused on developing a transcatheter solution for functional mitral valve regurgitation. The company's core technology involves an implant and delivery system designed to augment the anterior leaflet, thereby enlarging its area and creating coaptation of the leaflets. Leafix Medical operates within the Medical Devices and Medical Treatment & Therapeutics sectors, serving the healthcare industry, particularly providers.

Strategic signal

In July 2025, Leafix Medical secured a Seed funding round, indicating strong early investor confidence in its novel transcatheter solution for functional mitral regurgitation. This investment, led by Pitango HealthTech, validates the company's innovative approach to addressing a significant cardiovascular health challenge and signals potential for rapid development and market entry in the medical device sector.

Company Intelligence Q&A

What is Leafix Medical's primary focus?

Leafix Medical is developing a transcatheter solution for functional mitral valve regurgitation, utilizing an implant and delivery system to augment the anterior leaflet and improve coaptation.

When was Leafix Medical founded?

Leafix Medical was founded in January 2025.

Who is a key founder of Leafix Medical?

Ron Szekely is a co-founder and CEO of Leafix Medical.

What was a significant funding event for Leafix Medical?

In July 2025, Leafix Medical secured a Seed funding round, with.

What is Leafix Medical's product development stage?

Leafix Medical is currently in the Research & Development (R&D) product stage, focusing on advancing its transcatheter solution for functional mitral valve regurgitation.